BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. - Wikidata - wikimedia - TriplyDB

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

http://www.wikidata.org/entity/Q34047394

about

Epigenetic Strategies to Boost Cancer Immunotherapies.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 BET inhibitors: a novel epigenetic approach.Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma The cancer epigenome: Concepts, challenges, and therapeutic opportunities.Marked for death: targeting epigenetic changes in cancer.BET Bromodomain Proteins as Cancer Therapeutic Targets.MYC: Master Regulator of Immune Privilege.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.BET inhibitors as novel therapeutic agents in breast cancer.BETting on combination to overcome PARPi resistance.Ovarian cancer: how can resistance to chemotherapy be tackled?Chromatin dependencies in cancer and inflammation.Improvement of Antitumor Therapies Based on Vaccines and Immune-Checkpoint Inhibitors by Counteracting Tumor-Immunostimulation.A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.The MYC oncogene is a global regulator of the immune response.Immunotherapy With Human Gamma Delta T Cells-Synergistic Potential of Epigenetic Drugs?Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages.Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors Emerging role of precision medicine in biliary tract cancers Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells Targeting the Microenvironment in High Grade Serous Ovarian Cancer

P2860

Q33838340-3A0ABF27-8B27-43C3-9B3F-2916BF577AF1 Q34048020-EAEE11CD-3584-4E81-8AF5-20483613D3B5 Q38609772-B03927E3-4D27-455B-BCE3-A317F6AC9005 Q38637914-A6973A91-B92D-43E3-9602-03A68C82C549 Q38719539-F5D60906-CD54-4547-8B08-CDAC9178A897 Q38743881-68BA72E2-B41E-449C-835D-0A60A4F860E7 Q38747872-2F74B0BF-4E94-4DB7-8185-FDE255FD7166 Q39071349-1B43D3B4-9DEA-4A33-9906-005C764340AC Q39149130-AB9AC754-D6DD-4F54-96F5-0ABF787A3958 Q42042886-609BD459-3677-46AB-82A6-C6376376AB26 Q42378528-E439D80F-EF27-4336-A143-781E48881DFD Q47093793-8A9AD4BA-E2C2-458D-9658-7B3400E1EF98 Q47813897-18493C6E-175A-42D9-A7CE-B46287154A03 Q49565575-1EE6550A-1AFB-42B5-910A-19C4BAACA0E3 Q49872011-2FC17F64-AFBF-4E3F-9760-6D9663379EF5 Q52579555-F13CA8E1-7C45-4C09-9CF4-C582EB914C8B Q52630284-6773B3BD-F4D8-42D2-AE13-609E3778F7BA Q52679779-C3B21019-5BFB-41C6-9203-A8AB70B31DA3 Q52688134-FEABAFDB-E956-4424-B85C-ABBA52EB7B26 Q52728139-B188E113-1C7A-4376-88F8-B226A87BF6E3 Q55030400-AC3B359B-64D9-40DF-AB29-301FA119842D Q55266134-C374D1F8-6407-44A9-9AD0-6B2403CED139 Q56892267-219D827F-46AA-4610-A397-709A0CB11366 Q57138348-0C4009EF-F75E-4134-8014-8FD7EF3F7396 Q57298169-BAED0A52-0409-4ECB-9B0C-6CDF4E23F528 Q58693136-936513D4-378E-484D-A53F-30632700AC0F Q58763499-D40922CB-020B-431A-8DC2-5799128E9F3C Q58789499-DD5F5F93-4383-4CE1-9386-BD63A1118C6D

P2860

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

http://www.wikidata.org/entity/Q34047394

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@ast

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@en

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@nl

type

label

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@ast

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@en

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@nl

prefLabel

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@ast

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@en

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

@nl

P1433

Q34047394-ACB21C3C-A46B-41C0-843C-7A4E4E419C82

P1476

Q34047394-57A5DF1C-E07E-43B5-AA02-AD6F67288665

P2093

Q34047394-1E5240E0-11ED-4CF6-B502-F6ACAA9DFBF5

Q34047394-45DE4AE2-0451-4DC3-8038-1365EA6D5AB0

Q34047394-463F6B47-076C-4C24-988E-BA43F85B3AED

Q34047394-49413135-A660-48B7-96DF-845319803F47

Q34047394-5026AB6B-1182-416B-948C-DA6DACE0D1CC

Q34047394-6187B84F-C67D-45EF-BF8D-6209AA4EF759

Q34047394-67101C1E-4F67-4AE9-B853-5BAB16193BAE

Q34047394-C980A8CD-8894-4378-95A4-F696EBB76AD3

Q34047394-EC1B9EAF-3BE4-4F6A-9AA5-0746E34BA9EE

Q34047394-F17BB63A-5F1E-4AD8-8259-61F037B0AFC5

P2860

Q34047394-04C8B871-79F9-4A08-803C-A86EA11ADD8C

Q34047394-095E4E67-68F5-43C5-ACE7-824C762B3D67

Q34047394-1FF91933-6C3C-47AA-9D1C-7B6176C4AD2B

Q34047394-2ABE088B-40ED-4FD7-9793-7B5ED2BAE764

Q34047394-38C097C9-EDE7-45DD-B005-1BB51C99DA7B

Q34047394-49B24A55-730C-4F3F-AECC-8AA80E912BBC

Q34047394-5175F300-6962-40B4-9A0A-E4310F72EB42

Q34047394-56A6F6B2-2ADA-4A24-A83F-48F26E68E0C7

Q34047394-61A99177-EEBD-47D0-8A71-29D6C8C06246

Q34047394-68176712-4F67-4758-9CBA-2C725CA94ABD

P304

Q34047394-75C26D17-796F-44C9-A4C6-18904B3E3429

P31

Q34047394-9E0E6A55-637B-41DD-85E8-5E529DF030D1

P356

Q34047394-00BBECF9-80DC-4FB6-AF6A-B8372230FEBB

P433

Q34047394-52F97598-95F0-4683-A7B5-D50442875FF9

P478

Q34047394-4BFB9DE3-23E5-4484-9DCD-0FF3979C4B6C

P50

Q34047394-B2DB3DE1-F255-431D-8F95-58572FEB379D

P577

Q34047394-5C4362A7-57EE-4BDE-BB6C-80CAF1A5F7B3

P698

Q34047394-2C4E8B6D-0BCA-4111-A6E3-07C837593477

P932

Q34047394-70404C54-D99C-47CD-AF69-AA40A1ADE7ED

P356

J.CELREP.2016.08.032

P1433

P1476

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

@en

P2093

Andrew V Kossenkov

http://www.w3.org/2001/XMLSchema#string

Fee Bengsch

http://www.w3.org/2001/XMLSchema#string

Hengrui Zhu

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jose R Conejo-Garcia

http://www.w3.org/2001/XMLSchema#string

Melanie R Rutkowski

http://www.w3.org/2001/XMLSchema#string

Michael J Allegrezza

http://www.w3.org/2001/XMLSchema#string

Nikolaos Svoronos

http://www.w3.org/2001/XMLSchema#string

Rugang Zhang

http://www.w3.org/2001/XMLSchema#string

Yuhki Yokoyama

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Suppression of inflammation by a synthetic histone mimic

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Immune checkpoint blockade: a common denominator approach to cancer therapy

Targeting bromodomains: epigenetic readers of lysine acetylation

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Big opportunities for small molecules in immuno-oncology.

P304

2829-2837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2016.08.032

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin G Bitler

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27626654

http://www.w3.org/2001/XMLSchema#string

P932

5177024

http://www.w3.org/2001/XMLSchema#string